FOSTER CITY, Calif.,
Sept. 1, 2016 /PRNewswire/
-- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today
announced that the Company will present a corporate overview and
business update at two investor conferences in September 2016.
- Friedhelm Blobel, PhD, Chief
Executive Officer, will present at the Rodman & Renshaw
18th Annual Global Investment Conference on Tuesday, September 13, 2016 at 5:30 pm ET, at The Lotte New York Palace
Hotel.
- Wilson W. Cheung, Chief
Financial Officer, will present at the Aegis Capital Corp. Annual
Growth Conference at 9:30 am PT on
Wednesday, September 21, 2016, at The
Encore at Wynn Las Vegas.
To access the live audio webcast of these presentations, please
log on through a link located in the Investor Relations section of
SciClone's website at www.sciclone.com, under the Calendar of
Events tab. A replay of the webcast will be available one hour
after the conclusion of the live events.
About SciClone
SciClone Pharmaceuticals is a revenue-generating, specialty
pharmaceutical company with a substantial commercial business in
China and a product portfolio
spanning major therapeutic markets including oncology, infectious
diseases and cardiovascular disorders. SciClone's proprietary
lead product, ZADAXIN® (thymalfasin), is approved
in over 30 countries and may be used for the treatment of hepatitis
B (HBV), hepatitis C (HCV), and certain cancers, and as an immune
system enhancer, according to the local regulatory approvals. The
Company has successfully in-licensed and commercialized products
with the potential to become future market leaders and to drive the
Company's long-term growth, including DC Bead®, a novel
treatment for liver cancer now approved in China, and several other products in late
stage development in China.
Through its promotion business with pharmaceutical partners,
SciClone also markets multiple branded products in China which are therapeutically
differentiated. SciClone is a publicly-held corporation based in
Foster City, California, and
trades on the NASDAQ Global Select Market under the symbol SCLN.
For additional information, please visit www.sciclone.com.
Forward-Looking Statements
This press release contains forward-looking statements regarding
expected financial results and expectations. Readers are urged to
consider statements that include the words "may," "will," "would,"
"could," "should," "might," "believes," "estimates," "projects,"
"potential," "expects," "plans," "anticipates," "intends,"
"continues," "forecast," "designed," "goal," "unaudited,"
"approximately" or the negative of those words or other comparable
words to be uncertain and forward-looking. These statements are
subject to risks and uncertainties that are difficult to predict
and actual outcomes may differ materially. Please also refer
to other risks and uncertainties described in SciClone's filings
with the SEC. All forward-looking statements are based on
information currently available to SciClone and SciClone assumes no
obligation to update any such forward-looking statements.
SciClone, SciClone Pharmaceuticals, the SciClone
Pharmaceuticals design, the SciClone logo and ZADAXIN are
registered trademarks of SciClone Pharmaceuticals, Inc. in
the United States and numerous
other countries.
Corporate
Contacts
|
|
Wilson W.
Cheung
|
Jane Green
|
Chief Financial
Officer
|
Investors/Media
|
650.358.3434
|
650.358.1447
|
wcheung@sciclone.com
|
jgreen@sciclone.com
|
Logo - http://photos.prnewswire.com/prnh/20150722/240358LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/sciclone-to-present-at-two-investor-conferences-in-september-2016-300321744.html
SOURCE SciClone Pharmaceuticals, Inc.